Stock Financial Ratios, Dividends, Split History

VSI / Vitamin Shoppe, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)173.26
Enterprise Value ($M)169.04
Book Value ($M)186.46
Book Value / Share7.69
Price / Book0.93
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Shares Outstanding 24,203,144
Weighted Average Number Of Diluted Shares Outstanding 23,137,977
Preferred Stock Shares Outstanding 0
Weighted Average Number Of Shares Outstanding Basic 23,137,977
Common Stock Shares Outstanding 24,021,948
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-1.29
Return on Assets (ROA)-0.34
Return on Equity (ROE)-0.57
Balance Sheet (mrq) ($M)
Quick Ratio0.44
Current Ratio1.88
Income Statement (mra) ($M)
Disposal Group Including Discontinued Operation Revenue0.00
Sales Revenue Net1,178,694,000.00
Shipping And Handling Revenue2,200,000.00
Operating Income-262.81
Net Income-252.15
Earnings Per Share Basic-10.90
Earnings Per Share Diluted-10.90
Cash Flow Statement (mra) ($M)
Cash From Operations56.23
Cash from Investing-55.45
Cash from Financing56.23
Identifiers and Descriptors
Central Index Key (CIK)1360530
Related CUSIPS
92849E105 92849E109 92849E901 00928E105 92849E951
Industry Groups
SIC 54 - Food Stores

Split History

Stock splits are used by Vitamin Shoppe, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

NVRO: Nevro Corp Analysis and Research Report

2018-07-06 - Asif

Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...

Related News Stories

Give These 4 Retail Stocks A Miss As Earnings Season Arrives

2018-07-13 zacks
Dark clouds loom over markets even as Wall Street is gearing up to witness an impressive earnings season. The concerns are pretty valid given Trump’s threat to impose another 10% tariff on $200 billion Chinese goods following action on $34 billion worth of imports last week. The trade hostility between the United States and China has been influencing the market for quite some time now. However, its high time that you bury the trade related fears and rejig your portfolio. (10-0)

20 Small-Cap Stocks With the Potential for Outsized Gains | InvestorPlace

2018-07-12 investorplace
Some market components, such as small-capitalization companies, require little coaxing. Whether it’s their potential to produce incredible gains, or the chance to get in early on a burgeoning industry, small-cap stocks present enticing opportunities. And while we should all be aware of their highly risky reputation, most investment strategies benefit from their inclusion. (86-3)

GNC: Our Valuation

2018-06-21 seekingalpha
We fulfill our earlier commitment of presenting our updated valuation of GNC based on new financial information since our earlier effort based on assumptions regarding debt refinancing and corporate transactions. (10-0)

The Insiders Are Buying: Are You?

2018-06-21 seekingalpha
Insiders are buying up shares at depressed prices giving investors reason to believe they are confident in the turnaround. (53-0)

Vitamin Shoppe: Buy The Turnaround

2018-06-11 seekingalpha
Vitamin Shoppe (VSI) is seeing its share price bid higher as management works to improve its fundamental operations. In recent years, management has worked to expand the company’s digital presence to grow customer conversions. Moreover, a bulk of the company’s sales comes from repeat buyers, leading management to target this group for further top-line growth. Its stock looks to have bottomed after years of decline. (10-0)

CUSIP: 92849E101